FI20002127A0 - Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi - Google Patents

Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Info

Publication number
FI20002127A0
FI20002127A0 FI20002127A FI20002127A FI20002127A0 FI 20002127 A0 FI20002127 A0 FI 20002127A0 FI 20002127 A FI20002127 A FI 20002127A FI 20002127 A FI20002127 A FI 20002127A FI 20002127 A0 FI20002127 A0 FI 20002127A0
Authority
FI
Finland
Prior art keywords
pca
patients
psa
antibody
chain
Prior art date
Application number
FI20002127A
Other languages
English (en)
Swedish (sv)
Inventor
Kim Pettersson
Timo Loevgren
Hans Lilja
Pauliina Nurmikko
Original Assignee
Artic Partners Oy Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artic Partners Oy Ab filed Critical Artic Partners Oy Ab
Priority to FI20002127A priority Critical patent/FI20002127A0/fi
Publication of FI20002127A0 publication Critical patent/FI20002127A0/fi
Priority to JP2002530851A priority patent/JP5254517B2/ja
Priority to AT01972118T priority patent/ATE425460T1/de
Priority to DE60137949T priority patent/DE60137949D1/de
Priority to EP01972118A priority patent/EP1320756B1/en
Priority to PCT/FI2001/000834 priority patent/WO2002027323A1/en
Priority to ES01972118T priority patent/ES2322432T3/es
Priority to AU2001291911A priority patent/AU2001291911A1/en
Priority to US10/381,132 priority patent/US7872104B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI20002127A 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi FI20002127A0 (fi)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
JP2002530851A JP5254517B2 (ja) 2000-09-27 2001-09-26 新規抗体、イムノアッセイおよび前立腺癌検出方法
AT01972118T ATE425460T1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
DE60137949T DE60137949D1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
EP01972118A EP1320756B1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection
PCT/FI2001/000834 WO2002027323A1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection
ES01972118T ES2322432T3 (es) 2000-09-27 2001-09-26 Nuevo anticuerpo, inmunoensayo y procedimiento para la deteccion del cancer de protasta.
AU2001291911A AU2001291911A1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection
US10/381,132 US7872104B2 (en) 2000-09-27 2001-09-26 Antibody, immunoassay and method for prostate cancer detection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Publications (1)

Publication Number Publication Date
FI20002127A0 true FI20002127A0 (fi) 2000-09-27

Family

ID=8559172

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Country Status (9)

Country Link
US (1) US7872104B2 (fi)
EP (1) EP1320756B1 (fi)
JP (1) JP5254517B2 (fi)
AT (1) ATE425460T1 (fi)
AU (1) AU2001291911A1 (fi)
DE (1) DE60137949D1 (fi)
ES (1) ES2322432T3 (fi)
FI (1) FI20002127A0 (fi)
WO (1) WO2002027323A1 (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754812B (zh) 2007-05-04 2013-06-26 克拉洛诊断仪器公司 流体连接器和微流体系统
DK2391451T3 (en) 2009-02-02 2018-10-15 Opko Diagnostics Llc STRUCTURES FOR MANAGING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES
WO2013063312A1 (en) * 2011-10-25 2013-05-02 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
KR102362358B1 (ko) 2011-10-28 2022-02-15 프레닥스 에이비 치료제 및 이의 용도
CN108108590A (zh) * 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
EP2833150A4 (en) * 2012-03-30 2016-03-23 Univ Kyoto URINBIOMARKER FOR USE IN A TEST ON PROSTATE CANCER
KR102574537B1 (ko) 2013-11-19 2023-09-06 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
FI3123381T3 (fi) 2014-03-28 2023-11-27 Opko Diagnostics Llc Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä
CN107406510B (zh) * 2015-03-27 2022-02-18 欧普科诊断有限责任公司 前列腺抗原标准品及其用途
RU2753677C2 (ru) * 2015-10-05 2021-08-19 Фредакс Аб Полипептиды антител и их применение
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635575A1 (en) * 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
JPH10150999A (ja) * 1996-11-22 1998-06-09 Eiken Chem Co Ltd ヒト前立腺特異抗原−α１−アンチキモトリプシン複合体に対するモノクローナル抗体及びそれを用いたヒト前立腺特異抗原−α１−アンチキモトリプシン複合体の免疫学的検出法
US5858685A (en) * 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
CA2286090C (en) * 1997-04-30 2013-01-08 Hybritech Incorporated Forms of prostate specific antigen and methods for their detection
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone

Also Published As

Publication number Publication date
EP1320756B1 (en) 2009-03-11
AU2001291911A1 (en) 2002-04-08
ATE425460T1 (de) 2009-03-15
EP1320756A1 (en) 2003-06-25
DE60137949D1 (de) 2009-04-23
WO2002027323A1 (en) 2002-04-04
US7872104B2 (en) 2011-01-18
JP2004509934A (ja) 2004-04-02
JP5254517B2 (ja) 2013-08-07
ES2322432T3 (es) 2009-06-22
US20040101914A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
Oesterling Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
Mönig et al. Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma
Mikolajczyk et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
Fritzsche et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer
Cho et al. High level of urokinase‐type plasminogen activator is a new prognostic marker in patients with gastric carcinoma
Fritzsche et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
FI20002127A0 (fi) Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
Chan et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
Shariat et al. New blood‐based biomarkers for the diagnosis, staging and prognosis of prostate cancer
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
EA023466B1 (ru) Способ определения стволовых клеток рака молочной железы и применение антагонистов cxcr1 для лечения рака
TR200001253T2 (tr) Tümöre özel antijenler
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
Strojan et al. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients
Zargaran et al. Immunohistochemical evaluation of type IV collagen and laminin‐332 γ2 chain expression in well‐differentiated oral squamous cell carcinoma and oral verrucous carcinoma: a new recommended cut‐off
ATE350662T1 (de) Markerproteine für prostatakrebs
Moul et al. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen
Oh et al. Comparisons of remnant primary, residual, and recurrent gastric cancer and applicability of the 8th AJCC TNM classification for remnant gastric cancer staging
AU4623599A (en) Method for diagnosing an adenocarcinoma or a benign prostate pathology
Chhieng et al. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma
Haese et al. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade
EP1539818A4 (en) COMPOSITIONS AND ITS USES FOR THE IDENTIFICATION AND TARGETTING OF PROVASOPRESSINEXPRIMATING CANCER CELLS
Bussemakers Changes in gene expression and targets for therapy
Peltola et al. Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades